{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:48:06Z","timestamp":1776919686892,"version":"3.51.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors targeting PD-1\/PD-L1 and CTLA-4 have substantially improved outcomes in multiple malignancies, but they may also trigger dysregulated immune activation accompanied by systemic toxic effects and multi-organ injury. Although immune-related adverse events are increasingly recognized in oncology practice, the clinical architectures through which immune toxicity progresses across organ systems, and the biological pathways that may support earlier risk assessment and mechanism-informed intervention, remain insufficiently defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a translational multicohort study integrating clinical phenotyping, biomarker modeling, and mechanistic validation. In a development cohort derived from a large United States electronic health record database, cross-organ co-occurrence networks were used to characterize reproducible patterns of organ involvement, and data-driven phenotypes were derived using non-negative matrix factorization and hierarchical clustering, followed by landmark outcome analyses. A biomarker-informed risk framework integrating immune-toxicity features with conventional severity indices was subsequently evaluated in an independent United States external validation cohort. To assess biological concordance across clinical and experimental levels, parallel analyses were conducted in biospecimens from a prospectively enrolled single-center Chinese patient cohort and in preclinical models, with emphasis on pyroptosis-related signaling, myeloid inflammatory activation, endothelial\u2013coagulation coupling, and mitochondrial injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Immune-toxicity-associated systemic injury demonstrated stable cross-system architectures that segregated into clinically interpretable phenotypes with graded mortality risk, organ-support requirements, and recovery trajectories. Compared with conventional severity assessment alone, incorporation of immune-toxicity biomarker axes improved risk discrimination and supported more refined patient stratification across cohorts. Mechanistic analyses further identified prominent activation of pyroptosis-related pathways together with mitochondrial stress, while myeloid-dominated inflammation and endothelial activation were associated with propagation of systemic injury across organs. These findings linked phenotypic heterogeneity at the clinical level with biologically plausible injury programs observed in patient biospecimens and experimental systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study establishes a translational framework connecting clinical phenotypes, biomarker-based risk stratification, and biologically supported injury pathways in immune checkpoint inhibitor-associated systemic toxicity. The findings may support earlier recognition and structured clinical assessment of patients with suspected immune-toxicity-associated organ injury and provide a rationale for future mechanism-guided intervention studies. Further multicenter, diagnostically controlled, and ethnically diverse investigations are needed to determine the generalizability of these findings and their utility in distinguishing immune-toxicity-associated critical illness from other causes of systemic inflammation and organ failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1808024","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:22:12Z","timestamp":1776918132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic drivers of PD-L1\/CTLA-4 checkpoint inhibitor\u2013associated immune toxicity and systemic organ injury"],"prefix":"10.3389","volume":"16","author":[{"given":"Junfeng","family":"Chen","sequence":"first","affiliation":[{"name":"Center of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minqqiang","family":"Gao","sequence":"additional","affiliation":[{"name":"Center of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Min","sequence":"additional","affiliation":[{"name":"Center of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13613-023-01122-z","article-title":"ICU admission for solid cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Toffart","year":"2023","journal-title":"Ann Intensive Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7302","article-title":"Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Lin","year":"2024","journal-title":"Cancer Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-025-08155-x","article-title":"Life-threatening immune-related adverse events in the intensive care unit: a narrative review","volume":"51","author":"Pichon","year":"2025","journal-title":"Intensive Care Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Letcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"102936","DOI":"10.1016\/j.ctrv.2025.102936","article-title":"From ICI to ICU: a systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors and admitted to the intensive care unit","volume":"136","author":"van Dijk","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1186\/s12885-025-14733-5","article-title":"Adverse drug events of immune checkpoint inhibitors: a retrospective, descriptive real-world data analysis","volume":"25","author":"Auch","year":"2025","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-025-02344-4","article-title":"Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives","volume":"24","author":"Huang","year":"2025","journal-title":"Mol Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","article-title":"Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1647944","article-title":"Infectious adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on the FAERS database","volume":"16","author":"Song","year":"2025","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.02.005","article-title":"Immune checkpoint inhibitor-related myocarditis with or without concomitant myopathy: clinical findings and cardiovascular outcomes","volume":"7","author":"Itzhaki Ben Zadok","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.07.002","article-title":"Steroids in immune checkpoint inhibitor myocarditis","volume":"6","author":"Palaskas","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00687.2024","article-title":"Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review","volume":"328","author":"Jensen","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvdsp.2023.04.021","article-title":"Diagnostic value of the International Society of Cardio-Oncology definition for suspected immune checkpoint inhibitor-associated myocarditis","volume":"12","author":"Deharo","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1699894","article-title":"Endothelial dysfunction and hemostatic imbalance in CAR T-cell-associated toxicities: pathophysiological insights and the role of circulating biomarkers","volume":"16","author":"Moreno-Casta\u00f1o","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B19","doi-asserted-by":"publisher","first-page":"502135","DOI":"10.1016\/j.medine.2025.502135","article-title":"What should intensivists know about immune checkpoint inhibitors and their side effects","volume":"49","author":"Aleksandrov","year":"2025","journal-title":"Med Intensiva (Engl Ed)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis: a report of the American college of cardiology solution set oversight committee","volume":"85","author":"Drazner","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.10.005","article-title":"Cardiovascular and oncological outcomes in immune checkpoint inhibitor-induced myocarditis: balancing perspectives","volume":"5","author":"Cheng","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-024-00599-y","article-title":"Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808024\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:22:13Z","timestamp":1776918133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808024\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1808024"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1808024","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"1808024"}}